Zhongdang Xiao

State Key Laboratory Of Bioelectronics
Nanjing, China

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 34 publications

Harnessing pyroptosis in breast cancer therapy: immunological mechanisms and emerging biomaterial strategies.

Harnessing pyroptosis in breast cancer therapy: immunological mechanisms and emerging biomaterial strategies.

Journal: Cell death discovery
Published: July 22, 2025

Dual-target CAR-T therapy for ovarian cancer: synergistic targeting of MSLN and B7H3 enhances anti-tumor efficacy and overcomes antigen heterogeneity.

Dual-target CAR-T therapy for ovarian cancer: synergistic targeting of MSLN and B7H3 enhances anti-tumor efficacy and overcomes antigen heterogeneity.

Journal: Oncogene
Published: July 06, 2025

Enhancing the antitumor activity of CD19/BCMA CAR-T cells in vitro with a PD1IL7R chimeric switch receptor.

Enhancing the antitumor activity of CD19/BCMA CAR-T cells in vitro with a PD1IL7R chimeric switch receptor.

Journal: Cellular immunology
Published: May 06, 2025

Engineered promoter-free insulin-secreting cells provide closed-loop glycemic control.

Engineered promoter-free insulin-secreting cells provide closed-loop glycemic control.

Journal: Life sciences
Published: January 15, 2025

Cancer-associated fibroblast-secreted FGF7 as an ovarian cancer progression promoter.

Cancer-associated fibroblast-secreted FGF7 as an ovarian cancer progression promoter.

Journal: Journal of translational medicine
Published: November 02, 2023

MicroRNA-18a prevents senescence of mesenchymal stem cells by targeting CTDSPL.

MicroRNA-18a prevents senescence of mesenchymal stem cells by targeting CTDSPL.

Journal: Aging
Published: August 29, 2023

Engineered extracellular vesicles mediated CRISPR-induced deficiency of IQGAP1/FOXM1 reverses sorafenib resistance in HCC by suppressing cancer stem cells.

Engineered extracellular vesicles mediated CRISPR-induced deficiency of IQGAP1/FOXM1 reverses sorafenib resistance in HCC by suppressing cancer stem cells.

Journal: Journal of nanobiotechnology
Published: February 22, 2023

Stem cells therapy for diabetes: from past to future.

Stem cells therapy for diabetes: from past to future.

Journal: Cytotherapy
Published: January 26, 2023

Microvesicles: the functional mediators in sorafenib resistance.

Microvesicles: the functional mediators in sorafenib resistance.

Journal: Cancer drug resistance (Alhambra, Calif.)
Published: December 21, 2021

Microvesicles - promising tiny players' of cancer stem cells targeted liver cancer treatments: The interesting interactions and therapeutic aspects.

Microvesicles - promising tiny players' of cancer stem cells targeted liver cancer treatments: The interesting interactions and therapeutic aspects.

Journal: Pharmacological research
Published: February 17, 2021

Microvesicles mediate sorafenib resistance in liver cancer cells through attenuating p53 and enhancing FOXM1 expression.

Microvesicles mediate sorafenib resistance in liver cancer cells through attenuating p53 and enhancing FOXM1 expression.

Journal: Life sciences
Published: September 26, 2020

Epithelial cell -derived microvesicles: A safe delivery platform of CRISPR/Cas9 conferring synergistic anti-tumor effect with sorafenib.

Epithelial cell -derived microvesicles: A safe delivery platform of CRISPR/Cas9 conferring synergistic anti-tumor effect with sorafenib.

Journal: Experimental cell research
Published: March 04, 2020
Showing 1-12 of 34

Last Updated: 09/26/2026